Skip to main content
Aprea Therapeutics, Inc. logo

Aprea Therapeutics, Inc. — Investor Relations & Filings

Ticker · APRE ISIN · US03836J1025 US Professional, scientific and technical activities
Open in API
Filings indexed 405 across all filing types
Latest filing 2023-05-08 Board/Management Inform…
Country US United States of America
Listing US APRE

About Aprea Therapeutics, Inc.

https://www.aprea.com/

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops and commercializes novel cancer therapeutics. The company focuses on precision oncology through a synthetic lethality-based approach, targeting DNA Damage Response (DDR) pathways. Its pipeline consists of small molecule therapeutics designed to exploit vulnerabilities associated with cancer cell mutations, aiming to maximize clinical activity and selectivity while minimizing toxicity. Aprea Therapeutics is conducting clinical trials to evaluate its programs in patients with advanced solid tumors.

Recent filings

Filing Released Lang Actions
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The key content is the appointment of a new director to the Board of Directors, including details about the director's background and stock option grant. The document specifically falls under Item 5.02, which relates to changes in directors or certain officers. There is no financial data or earnings information, so it is not an earnings release or financial report. The document is not a proxy statement or AGM material. Therefore, the appropriate classification is Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management. The document length is sufficient and contains substantive information about the board change, not just a brief announcement or press release, so it is not Regulatory Filings (RNS) or Report Publication Announcement (RPA).
2023-05-08 English
10-K/A
Annual Report FY 2022
2023-04-28 English
FORM 8-K
Regulatory Filings
2023-04-18 English
10-K
Annual Report FY 2022
2023-03-30 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 30, 2023, by Aprea Therapeutics, Inc. It includes a press release announcing financial results for the quarter and fiscal year ended December 31, 2022, and an update on operations. It also includes a corporate presentation slide deck. The document explicitly states it is a "Current Report" pursuant to the Securities Exchange Act of 1934. Form 8-K filings are current reports used to announce major events that shareholders should know about, including earnings releases and other significant updates. The presence of a press release with financial results and operational updates aligns with an Earnings Release (ER). The document is not a full annual or quarterly report, nor is it a proxy, audit, or other specialized filing. Therefore, the best classification is Earnings Release (ER). The document length (7468 characters) supports it being a substantive filing rather than a brief announcement or certification. Confidence is high given the clear identification as a Form 8-K with earnings results and operational update.
2023-03-30 English
OWNERSHIP DOCUMENT
Director's Dealing
2023-03-13 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.